Researchers warn NIH divestment from research could hinder progress at a pivotal moment for advances in precision cancer medicine.
In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...
The firm's biologics license application for TLX250-CDx was granted priority review and a decision is expected in August.
The platform will enable on-site molecular profiling of liquid biopsy samples for cancer patient monitoring and treatment response prediction.
Based on early Phase I/II data, investigators at Cincinnati Children's are enrolling more patients with a telomere biology ...